Business
Completion of LupuzorT Pivotal Phase III Study
Completion of LupuzorT Pivotal Phase III Study.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 2020C Immupharma PLC 18 January 2018 \n\n 18 JANUARY 2018\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\nCompletion of Lupuzor™ Pivotal Phase III Study and Initiation of Follow Up Study\nImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, is now complete, following the last patient having attended their final assessment.\nFinal patient data from the trial are being collated and entered into the database, checked and analysed. This process is ongoing and top line results remain on track to be reported by the end of Q1 2018.\nAt completion, we continue to observe a robust safety profile over the 12 month period of patients' participation in the trial.\nSeparately, following requests from both Investigators and patients involved in the Phase III study, ImmuPharma is initiating a \"follow-up\" study permitting eligible patients from the completed Phase III study, to receive Lupuzor™ (plus \"Standard of Care\") for a further six months in an open-label scheme. The results will be gathered as an \"extension\" open label study, independent of the pivotal Phase III trial which is now completed.\nCommenting on the trial update, Robert Zimmer (MD, PhD), Pr...